Therapeutic Antibody Engineering

1st Edition

Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry

Authors: William Strohl Lila Strohl
Hardcover ISBN: 9781907568374
eBook ISBN: 9781908818096
Imprint: Woodhead Publishing
Published Date: 16th October 2012
Page Count: 696
Tax/VAT will be calculated at check-out
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access

Table of Contents

List of figures

List of tables

List of acronyms, abbreviations, and definitions



About the authors

Chapter 1: Introduction to biologics and monoclonal antibodies


1.1 Introduction

1.2 Definitions of biologies

1.3 Recombinant protein therapeutics

1.4 MAbs and Fc fusion proteins (FcFPs)

1.5 General anatomy of a therapeutic IgG MAb

1.6 Naming convention for antibodies from different sources

Chapter 2: Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins


2.1 Overview of discovery and development of therapeutic MAbs and FcFPs

2.2 Market for MAbs and FcFPs

2.3 Currently and recently approved MAbs and FcFPs

Chapter 3: Antibody structure–function relationships


3.1 Introduction

3.2 Constant region structure/function

3.3 FAb structure/function

Chapter 4: Fundamental technologies for antibody engineering


4.1 Introduction

4.2 Hybridoma technology – the gateway for therapeutic monoclonal antibodies

4.3 Key recombinant DNA technologies

4.4 Generation of chimeric antibodies

4.5 Display technologies

4.6 Maturity timelines for biologies technologies

Chapter 5: Sources of antibody variable chains


5.1 Human antibody gene organization

5.2 Antibody gene rearrangement and diversity in vivo

5.3 Sources of antibody diversity

5.4 Class-switch recombination

5.5 Human variable gene usage

5.6 Variable region selection

5.7 Variable genes from non-human species

5.8 Use of variable genes from humans

Chapter 6: Variable chain engineering – humanization and optimization approaches


6.1 Introduction

6.2 Chimerization

6.3 Hum


The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering.

Key Features

  • Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships
  • Integration of knowledge across all areas of antibody engineering, development, and marketing
  • Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity


Microbiologists, biochemists, oncologists;


No. of pages:
© Woodhead Publishing 2012
Woodhead Publishing
eBook ISBN:
Hardcover ISBN:
Paperback ISBN:


An excellent balance between readability and depth of material.... The book is well referenced and provides plentiful opportunities to continue subject-specific learing., mAbs Journal
An excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility., Doody's Reviews

About the Authors

William Strohl Author

Dr William R. Strohl is Vice President of Biologics Research at Janssen R&D Biotechnology Center of Excellence, and was previously a leader in Merck’s efforts to discover therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. He has over 100 publications and several patents to his credit, and has edited two books.

Affiliations and Expertise

Johnson & Johnson Biotechnology Center of Excellence

Lila Strohl Author

Affiliations and Expertise

Medical Illustrator, USA